Repligen and Bio-Rad sold; Neurocrine Biosciences downgraded to a hold.

By Joe Duarte • September 1, 2015

Our EBIS portfolio triggered some sell stops this past week. Repligen and Bio-Rad have been removed from the STI Medical Profits portfolio. However, due to some potential pricing issues in the Flash Crash on 8/24/15 some of the pricing may or may not have been accurate. Thus, we are not removing Neurocrine Biosciences from the portfolio but are downgrading the shares to a HOLD.

Please see today’s issue of Smart Tech 50 Weekly Movers for more information on these transactions.

Stock Talk

Comments

Comments Guidelines

Add New Comments

You must be logged in to post to Stock Talk OR create an account

About The Author

Joe Duarte

Bio | Archive

Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine. He has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.